Kathryn Wynne Woodburn

US Patent:

7550433, Jun 23, 2009

Filed:

Jun 2, 2006

Appl. No.:

11/446593

Inventors:

Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Woodburn - Saratoga CA, US
Robert Barnett Naso - Menlo Park CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/16

US Classification:

514 12

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

US Patent:

7906485, Mar 15, 2011

Filed:

Jun 5, 2006

Appl. No.:

11/916416

Inventors:

Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Campbell CA, US
Robert Barnett Naso - Menlo Park CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/10
A61K 38/16

US Classification:

514 135, 514 214

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including pure red cell aplasia (PRCA). Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

US Patent:

7919461, Apr 5, 2011

Filed:

Jul 13, 2007

Appl. No.:

11/777500

Inventors:

Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Campbell CA, US
Robert Barnett Naso - Menlo Park CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/16

US Classification:

514 12

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

US Patent:

8324159, Dec 4, 2012

Filed:

Jul 23, 2008

Appl. No.:

12/178583

Inventors:

Anne-Marie Duliege - Palo Alto CA, US
Richard Stead - Bellevue WA, US
Kerstin Leuther - San Jose CA, US
Kathryn Wynne Woodburn - Saratoga CA, US
Robert Barnett Naso - Menlo Park CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/16

US Classification:

514 77, 514 54, 514 135, 514 154, 514 214

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

US Patent:

20010002251, May 31, 2001

Filed:

Jan 5, 2001

Appl. No.:

09/755824

Inventors:

Kathryn Woodburn - Sunnyvale CA, US
David Kessel - Beverly Hills MI, US

Assignee:

Pharmacyclics, Inc.

International Classification:

A61K009/14
A61K049/00
A61B008/13

US Classification:

424/009500

Abstract:

Texaphyrins are selectively retained in diseased tissue cells. When exposed to low level, non-thermal sonodynamic agent such as ultrasound, the texaphyrin-incorporated cells are selectively destroyed. There is provided a method of sonodynamic therapy by administering an effective amount of an intracellular sensitizer to a mammal in need thereof and providing an effective amount of a sonodynamic agent.

US Patent:

20020025298, Feb 28, 2002

Filed:

Aug 2, 2001

Appl. No.:

09/922350

Inventors:

Mark Blumenkranz - Portola Valley CA, US
Kathryn Woodburn - Sunnyvale CA, US
Richard Miller - Portola Valley CA, US
Stuart Young - Portola Valley CA, US

Assignee:

Pharmacyclics, Inc.

International Classification:

A61K049/00
A61K031/555
A61K031/407

US Classification:

424/009600, 514/185000, 514/410000, 604/020000

Abstract:

The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i.e., at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.

US Patent:

20020115649, Aug 22, 2002

Filed:

Jan 5, 2001

Appl. No.:

09/755795

Inventors:

Kathryn Woodburn - Sunnyvale CA, US
Stuart Young - Portola Valley CA, US

Assignee:

Pharmacyclics, Inc.

International Classification:

A61B005/055
A61K031/555
A61K031/409

US Classification:

514/185000, 514/410000, 604/020000

Abstract:

The present invention provides methods for treating disease of a subject in need thereof by sensitizing the effects of a co-therapeutic agent in macrophages. The method comprises administering a texaphyrin and a co-therapeutic agent to the subject. Texaphyrins are provided for enhancing the cytotoxicity of therapeutic agents in macrophage-mediated disease since texaphyrins have been shown to accumulate in macrophage.

US Patent:

20090209457, Aug 20, 2009

Filed:

Feb 13, 2009

Appl. No.:

12/370761

Inventors:

Anne-Marie Duliege - Palo Alto CA, US
Peter J. Schatz - Cupertino CA, US
Richard Stead - Bellevue WA, US
Kathryn Wynne Woodburn - Saratoga CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/12
A61P 7/00

US Classification:

514 11

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat or to prevent anti-erythropoietin (EPO) antibody-mediated disorders such as pure red cell aplasia (PRCA) that are characterized by anti-EPO antibodies. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.